MA50908A - Formulations de protéines de fusion vegfr-fc - Google Patents

Formulations de protéines de fusion vegfr-fc

Info

Publication number
MA50908A
MA50908A MA050908A MA50908A MA50908A MA 50908 A MA50908 A MA 50908A MA 050908 A MA050908 A MA 050908A MA 50908 A MA50908 A MA 50908A MA 50908 A MA50908 A MA 50908A
Authority
MA
Morocco
Prior art keywords
vegfr
fusion protein
protein formulations
formulations
fusion
Prior art date
Application number
MA050908A
Other languages
English (en)
Inventor
William J Callahan
Robert Matthew Fesinmeyer
Rahul Rajan Kaushik
Sai Chakradhar Padala
Yael Wexler-Cohen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA50908A publication Critical patent/MA50908A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050908A 2017-11-17 2018-11-16 Formulations de protéines de fusion vegfr-fc MA50908A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587733P 2017-11-17 2017-11-17
US201862618904P 2018-01-18 2018-01-18

Publications (1)

Publication Number Publication Date
MA50908A true MA50908A (fr) 2020-09-23

Family

ID=65041879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050908A MA50908A (fr) 2017-11-17 2018-11-16 Formulations de protéines de fusion vegfr-fc

Country Status (8)

Country Link
US (2) US12156900B2 (fr)
EP (1) EP3709971A2 (fr)
JP (2) JP7536640B2 (fr)
AU (3) AU2018368466B2 (fr)
CA (1) CA3082899A1 (fr)
MA (1) MA50908A (fr)
MX (2) MX2020005170A (fr)
WO (1) WO2019099921A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099921A2 (fr) 2017-11-17 2019-05-23 Amgen Inc. Formulations de protéines de fusion vegfr-fc
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
WO2019173767A1 (fr) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Formulations aqueuses stables d'aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2020055123A1 (fr) * 2018-09-10 2020-03-19 삼성바이오에피스 주식회사 Composition liquide comprenant une protéine
WO2021050687A1 (fr) * 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Formulations aqueuses stables d'aflibercept
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
EP4190310A4 (fr) * 2020-07-31 2024-01-17 Celltrion, Inc. Préparation pharmaceutique stable
IL305010A (en) * 2021-02-17 2023-10-01 Arecor Ltd An aqueous preparation of a transgenic protein structure that includes an FC domain
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
US12240888B1 (en) * 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses
WO2025227916A1 (fr) 2024-04-29 2025-11-06 齐鲁制药有限公司 Composition comprenant de l'aflibercept et un variant de celui-ci, son procédé associé et son utilisation
JP2026054929A (ja) 2024-09-17 2026-03-30 キオクシア株式会社 メモリシステムおよび制御方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (fr) 2002-02-27 2009-06-16 Immunex Corporation Composition stabilisee du fragment fc et du recepteur tnf comprenant de l'arginine
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
EP1877438A2 (fr) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
CA3142945A1 (fr) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Formulations a tampon d'histidine d'antagoniste du vegf
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CA2654510C (fr) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Formulations antagonistes du vegf appropriees a une administration intravitreenne
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN103816115B (zh) 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
AU2012340107B2 (en) 2011-11-18 2017-06-15 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
WO2013096221A1 (fr) 2011-12-21 2013-06-27 Amgen Inc. Variants polypeptidiques fc ayant une liaison améliorée au récepteur de fc néonatal
CN107115294B (zh) 2012-01-19 2019-10-18 北京康弘生物医药有限公司 一种含有vegf拮抗剂的滴眼液
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
JP2015519373A (ja) 2012-06-01 2015-07-09 オプソテック コーポレイションOphthotech Corporation 抗pdgfアプタマーおよびvegf拮抗薬を含む組成物
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2014078627A1 (fr) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Formulations liquides pour des protéines de fusion tnfr:fc
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
MX390837B (es) 2015-10-16 2025-03-21 Regeneron Pharma Composiciones de proteinas estables.
MY200764A (en) * 2015-12-16 2024-01-14 Regeneron Pharma Compositions and methods of manufacturing protein microparticles
EP3407868A1 (fr) 2016-01-26 2018-12-05 Formycon AG Formulation liquide d'un antagoniste du vegf
WO2017168296A1 (fr) 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd Procédé de purification de protéines de fusion fc
KR101685532B1 (ko) 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
WO2018063963A1 (fr) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
WO2019020777A1 (fr) 2017-07-26 2019-01-31 Formycon Ag Formulation liquide d'un antagoniste du vegf
US20200255496A1 (en) 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
CN107595765A (zh) 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
WO2019099921A2 (fr) 2017-11-17 2019-05-23 Amgen Inc. Formulations de protéines de fusion vegfr-fc
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP3730126B1 (fr) 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Composition liquide comprenant un antagoniste du vegf
WO2019173767A1 (fr) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Formulations aqueuses stables d'aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2020055123A1 (fr) 2018-09-10 2020-03-19 삼성바이오에피스 주식회사 Composition liquide comprenant une protéine
US20210353713A1 (en) 2018-10-26 2021-11-18 Amgen Inc. Formulations comprising a tris buffer and a protein
EP3923907B1 (fr) 2019-02-13 2024-09-25 Novaliq GmbH Compositions et procédés pour le traitement de la néovascularisation oculaire
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
WO2021050687A1 (fr) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Formulations aqueuses stables d'aflibercept

Also Published As

Publication number Publication date
AU2024205240A1 (en) 2024-08-22
EP3709971A2 (fr) 2020-09-23
AU2018368466B2 (en) 2024-06-20
JP2024160287A (ja) 2024-11-13
WO2019099921A2 (fr) 2019-05-23
JP7536640B2 (ja) 2024-08-20
JP2021503485A (ja) 2021-02-12
MX2020005170A (es) 2020-10-16
US20200338164A1 (en) 2020-10-29
WO2019099921A3 (fr) 2019-06-27
CA3082899A1 (fr) 2019-05-23
AU2024205240B2 (en) 2026-05-14
AU2026203779A1 (en) 2026-06-04
US12156900B2 (en) 2024-12-03
JP7879902B2 (ja) 2026-06-24
US20250082726A1 (en) 2025-03-13
AU2018368466A1 (en) 2020-06-18
MX2025004779A (es) 2025-05-02

Similar Documents

Publication Publication Date Title
EP3880814A4 (fr) Protéine de fusion
IL268697A (en) Formulations
EP3519442A4 (fr) Protéines de fusion immunomodulatrices
DK3688162T3 (da) Formuleringer
IL262652A (en) Gdf15 fusion proteins and uses thereof
DK3292141T3 (da) Fusionsproteiner
PT3649151T (pt) Proteínas de suporte
EP3589662A4 (fr) Protéine monovalente inductible de fixation d' antigène
MA50657A (fr) Formulations de niraparib
DK3197453T3 (da) Kimært protein
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
MA50174A (fr) Formules de protéines de fusion vegfr-fc
EP3344278A4 (fr) Protéines de fusion immunoglobuline-insuline
DK3107562T3 (da) P97-ids-fusionsproteiner
EP3355931C0 (fr) Conjugués de protéines
EP3437776A4 (fr) Structure de joint
EP3368012A4 (fr) Formulations de lisinopril
DK3464331T3 (da) Stabiliserede præfusions-rsv f-proteiner
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
ZA202003845B (en) Fusion proteins
EP3801605A4 (fr) Formulation de protéine de fusion stable
EP3419651C0 (fr) Formulation de la protéine de fusion naglu améliorée
EP3688037A4 (fr) Protéines de fusion immunomodulatrices
EP3464384A4 (fr) Construction de protéines de fusion
IL280906A (en) Formulations of ag10